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Abstract: Narguileh is a water pipe. Narguileh smoking is a traditional pattern of smoking 
among Eastern Mediterranean women, publicly considered as a harmless entertainment. We 
performed a survey aimed at tracking chronic respiratory symptoms and alteration in respiratory 
functions in 77 female narguileh smokers, 77 cigarette smokers, and controls. A questionnaire 
about respiratory symptoms, quantity, and duration of smoking was completed by each woman, 
and a ﬂ  ow-volume loop was performed with all women. Women were then categorized in sub-
groups according to a cumulative smoking duration of over 5 years, and cumulative quantity 
of 50 kilograms smoked. We obtained 8 subgroups for quantity and 10 for duration. Results 
showed a higher proportion of chronic bronchitis in narguileh smokers compared with cigarette 
smokers for both quantity and duration (p value   0.001), as well as quasi-permanent alteration 
in maximum mid-expiratory ﬂ  ow (MMEF 25%–75%) in narguileh smokers compared with 
cigarette smokers (p value   0.001). Forced expired volume in one second was more altered in 
cigarette smokers than in narguileh smokers (p value   0.001). These results will help to raise 
health authority awareness that narguileh smoking is also dangerous for women.
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Introduction
Along with the relatively modern habit of cigarette smoking (Haglund 2000), women 
in the East Mediterranean region have been smoking narguileh water pipes for centu-
ries (Orlando 2000). This exercise is so widely spread that the narguileh smoking has 
become an inseparable part of the social image of women in their daily gatherings and 
that the untested idea of the narguileh being a harmless “toy” has become a common 
misconception even among physicians.
The narguileh is a water pipe (Figure 1) consisting of three main parts: a glass 
pitcher, a hose, and ﬁ  rebrands. The glass pitcher is half ﬁ  lled with water; a vertical tube 
is dipped in the water, and the upper tip of this tube is connected to a cup containing 
tobacco lit with brands. The pitcher is connected with another tube that reaches to the 
hose through which the smoke is drawn out by a series of puffs after bubbling through 
the water. This needs a high suction pressure and deep inspiratory effort to overcome 
the resistance of this long pathway. The tobacco used is called tombak, and takes the 
form of domestic pure tombak in Syria, meassel mixed with honey, and jurak, which 
is a tobacco fruit mixture cooked to produce a dark colored paste in Saudi Arabia 
(AL-Fayez et al 1980); tombak is burned with a piece of coal. The ignition temperature 
is 308 °C. (Omar and Salem 1996). Sheesha, shisha, chicha, Goza, hubble bubble, 
hookah, and narguile are synonymous to narguileh.
It is a social custom that a narguileh could be consumed by one woman or a group 
of women at during a session (Omar and Salem 1996; Orlando 2000). A pack of International Journal of COPD 2008:3(3) 406
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tombak is 40 g, and for each session 10 to 20 g of tombac 
are burned. The resulting smoke is inhaled over 1–1.5 hour-
long sessions. Every aspiration or puff lasts 4 seconds, with 
an 8-second rest (Brahim 1983).
At this time antismoking campaigns are mainly focused 
on the dangers of cigarette smoking. Nevertheless, in recent 
years, some papers have been published on potential health 
effects of narguileh smoking. In Syria, accordingly to unpub-
lished data from the health ministry, 17% of women in the 
coastal Mediterranean region smoke narguileh. 90% of them 
are urban, compared with 15% women cigarette smokers.
The general observation of our clinic in Syria indicates 
that narguileh-smoking women frequently share some chronic 
respiratory symptoms. This basic clinical observation led 
us to perform a survey aiming to compare prevalence of 
chronic respiratory symptoms and lung function in three 
groups of women: narguileh smokers, cigarette smokers, and 
nonsmokers (control). The results of the few former studies 
and our own study could induce changes in the public opinion, 
and help raise awareness within health authorities regarding 
this speciﬁ  c manner of smoking, and so encourage campaigns 
on the potential noxious effect of narguileh.
Materials and methods
Population
The survey was performed during the ﬁ  rst semester of 1994 
among 77 female narguileh smokers, and was completed in 
the ﬁ  rst semester of 1995 for 77 cigarette smokers and 100 
nonsmoker controls. All these women were older than 14 
(range 14–70) and were recruited from the general popula-
tion by a ﬁ  eld survey.
For a woman to be eligible, they were required to have 
no comorbidity, no respiratory symptoms related to factors 
other than smoking, and no exposure to other known risk 
factors in her daily life. None of the subjects smoked both 
narguileh and cigarettes. The nature and goals of the study 
were explained to the subjects who all gave their consent.
We had the ethical approval of the university council.
The questionnaire
The questionnaire (Figure 2) includes general sociodemo-
graphic variables (age, occupation, domestic location), infor-
mation on smoking for cigarette and narguileh (daily quantity 
and age of initiation), and respiratory symptoms: recurrent 
cough and sputum reﬂ  ecting chronic bronchitis (CBH) and 
dyspnea. Our question about the consumption of narguileh 
was locally designed and pilot-tested. The questions for 
CBH, cigarette smoking, and dyspnea were derived from the 
European Coal and Steel Community (ECSC) questionnaire 
(Minette 1989).
Women were categorized up to their cumulative duration 
of smoking by 5 years for time and to the cumulative quantity 
smoked by 50 kilos for quantity. We obtained 10 pairs of 
subgroups for time and 8 pairs of subgroups for quantity.
Duration of smoking was directly obtained from 
the questionnaire, while a quantitative evaluation of 
smoking was indirectly calculated according to the type 
of smoking:
For narguileh smokers, we used the following formula:
Q = S.q (g).T (days)/1000
Where:
• Q  = Cumulative quantity smoked in kg.
• S  = Number of sessions per day.
• q  = Quantity smoked per session in grams.
• T  = Duration of smoking in days.
•  n = number of smokers per session.
For cigarettes smokers, we used the following formula:
Q = N (g).T (days)/1000
Figure 1 Narguileh scheme.
Notes: Narguileh: consists of three parts: a glass pitcher, a hose through which the smoker draws bubbles of smoke from the tobacco burning in the ﬁ  rebrand cup through 
the water to cool the smoke.
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was invented when two 
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Turkey. International Journal of COPD 2008:3(3) 407
Chronic respiratory effect of narguileh smoking
Figure 2 The questionnaire: Name, age, occupation, domestic location, smoking, and clinical history.   The following box diagram describes the questionnaire.
Quantity of tombac by session? 
When did you smoke for the first time? 
How 
many  Daily quantity? 
Alone or with others?
With 
others 
Alone
Do you smoke narguileh?
YES
How many sessions a day?
NO 
Do you smoke cigarettes?
NO
  YES 
Did you have cough and 
phlegm? 
For at least 3 months/year 
For at least 2 years?  Do you have 
dyspnea?  International Journal of COPD 2008:3(3) 408
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Where:
• Q  = Cumulative quantity smoked in Kg.
• N  = Number of cigarettes per day (based on the fact that 
every cigarette contains one gram of tobacco).
• T  = Duration of smoking in days.
The result was divided by 1000 to convert g into kg.
Outcome measures: Five variables
Clinically: CBH and dyspnea (dysp).
-  Respiratory function: 1-The maximum mid-expiratory 
ﬂ  ow (MMEF), which is the volume delivered between 
25% and 75% of the forced vital capacity (FVC) reported 
in % of predicted value, reﬂ  ecting small airway alteration 
(Sherman 1992; Khaled and Joel 1997; West 2000) which 
is altered while FEV1 is still normal in smokers. MMEF 
25%–75% is also expressed in the medical literature by 
the forced expiratory ﬂ  ow rate (FEF 25%–75%) (West 
2000). It is also expressed by MMF (Shiraishi 1994).
-  2- Forced expiratory volume in one second (FEV1), FVC, 
and the ratio FEV1/FVC to determine the presence and 
severity of obstruction (expiratory airﬂ  ow limitation), 
with FEV1 reﬂ  ecting the increase in airway resistance 
(Sherman 1992; Quartier et al 1993; Desrues et al 1993; 
Khaled and Joel 1997; Gary et al 2000; GOLD 2005).
The ﬂ  ow – volume loop for all subjects was consequently 
analyzed. MMEF and FEV1 values were compared with normal 
predicted values, and were considered abnormal if less than 
80% of predicted. FEV1/FVC   70% was considered to reﬂ  ect 
obstruction (Sherman 1992; Quartier et al 1993; Desrues et al 
1993; Khaled and Joel 1997; Gary et al 2000; GOLD 2005).
Predicted values were considered for the CECA (Quartier 
et al 1993). The percentage of alteration for each variable 
(CBH, dypn, MMEF, FEV1, and FEV1⁄FVC) was calculated 
in all subgroups.
Data collection
Female narguileh smokers were ﬁ  rst visited at their homes 
during their daily gathering. The questionnaire was completed 
and they were then invited to the outpatient clinic for ofﬁ  ce 
spirometry and investigations for differential diagnosis and 
comorbidity. 100 were seen, 23 were excluded: 7 for comor-
bidities, 3 for noncooperating with spirometry, 11 refused 
to come for spirometry, and 2 for positive reversibility test 
with bronchodilators.
Data were collected by a well trained postgraduate 
pulmonary medical student who directly administered the 
questionnaire. Each participant performed ﬂ  ow – volume 
loop by automatic calibrated spirometer (Gary et al 2000). 
Flow – volume loops were repeated several times until three 
reliable tracings were obtained; the best two tracings for 
FVC are within 5% or 100 ml of each other, and the highest 
values were retained for the study analysis. As per the rec-
ommendations of the European Union (Quartier et al 1993), 
noncooperating subjects were rejected from the data.
The spirometric measurement was performed by a cali-
brated ofﬁ  ce spirometer at times when the women were not 
having any acute respiratory episodes. A reversibility test was 
performed when FEV1 was altered and those fully reversible 
were discarded.
We repeated this in 1995 for cigarette smokers and 100 
controls.
Statistical analysis
A descriptive analysis was ﬁ  rstly performed with Excel 
(Microsoft, Redmond, WA) for the subgroups, including 
clinical variables and functional variables. The proportion 
of alteration was calculated for CBH: presence of chronic 
cough and phlegm for at least three months/year for two 
years, dyspnea, MMEF, second FEV1, and FEV1/FVC%.
The second analysis was, in each pair of subgroups, the 
relationship among the percentage of alteration of the listed 
variables had been compared for narguileh and cigarette 
smokers, according to duration and cumulative quantity 
smoked.
Student test was performed with the statistical package, 
STATGRAPHICS 2.2 (StatPoint Inc., Herndon, VA), to 
determine the signiﬁ  cance of differences obtained between 
different pairs of subgroups of narguileh smokers or ciga-
rettes smokers, either for quantity or for duration (p value).
Results were presented in charts.
Results
The characteristics of our subjects are presented in Table 1. 
7% of narguileh smokers are employed, versus 64% of ciga-
rette smokers, and 58% of control. Cigarette smoking is 
linked with modernization.
Chronic bronchitis is more prevalent in narguileh smokers 
than cigarette smokers, either for cumulative quantity or for 
duration. The mean deviation for the quantity is 40 ± 3.8 
for cigarette smokers and 58 ± 3.8 for narguileh smokers 
(p value   0.001). For duration, the mean deviation is 
38 ± 3.81 for cigarette smokers, and 60 ± 3.81 for narguileh 
smokers (p value   0.001).
For MMEF, the mean deviation is constant for narguileh 
smokers, and signiﬁ  cantly higher than it is for cigarette smok-
ers, both for quantity and duration (p value   0.001).International Journal of COPD 2008:3(3) 409
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FEV1/FVC alteration and dyspnea are more presents 
in cigarette smokers; with a signiﬁ  cantly higher degree of 
obstruction expressed by a greater decrease in FEV1 in cigarettes 
smokers, both for quantity and duration (p   0.001).
Alteration of all these variables in control subjects is very 
low (5%–7%). Our principal results are presented in charts 
1, 2, 3, 4, 5, and 6.
Discussion
COPD is deﬁ  ned as a disease state characterized by airﬂ  ow 
limitation that is not fully reversible. The airﬂ  ow limitation 
is usually both progressive and associated with an abnormal 
inﬂ  ammatory response of the lungs to noxious particles or 
gases (GOLD 2005).
The role of cigarette smoke as chief predominant risk 
factor for CBH and COPD is established (Sherman 1992; 
Quartier et al 1993; Desrues et al 1993; Khaled and Joel 
1997; Gary et al 2000; GOLD 2005). But narguileh smok-
ing, which is traditional in oriental women, was rarely 
approached, being considered as safe in the public opinion. 
Our study was aimed at investigating the chronic respiratory 
effects of narguileh compared with cigarettes.
Our results show for the ﬁ  rst time that narguileh smoking 
in women provokes signiﬁ  cantly more CBH than cigarettes 
for the same quantity or duration (p value   0.001). Chronic 
bronchitis is deﬁ  ned as phlegm and cough during at least 
three months, and for at least two consecutive years. The 
deﬁ  nition of CBH is only clinical. FEV1 and FEV1/FVC could 
be normal and their alteration means the occurrence of COPD 
(Sherman 1992; Quartier et al 1993; Desrues et al 1993; 
Khaled and Joel 1997; Gary et al 2000; GOLD 2005).
Our results also show a quasi-constant alteration in small 
airways (2 mm of internal diameter) in narguileh smokers, 
expressed by MMEF   80% of predicted. No former study 
mentioned this quasi-constant alteration of MMEF 25%–75% 
in narguileh smokers regardless of cumulative quantity or 
duration of smoking, as demonstrated by our results, and 
that is significantly more important than for cigarettes 
(p value   0.001). No published data so far can explain this 
difference, and data on narguileh smoke diffusion and the 
size of particles are not available.
Although MMEF 25%–75% is not considered either 
for the diagnosis or for staging of COPD (GOLD 2005), it 
has been validated to reﬂ  ect early small airway alteration in 
current cigarette smokers. It is altered early in the natural 
history of COPD, especially before FEV1 (Sherman 1992; 
West 2000). It is also considered a risk factor for the devel-
opment of COPD (Poe et al 1982; Sherman1992; Desrues 
et al 1993; Quartier et al 1993; Gary et al 2000). A Japanese 
study (Sato and Kio 1997) found that the rate of decline of 
FEV1 is greater when MMEF is decreased. Studies even show 
that after quitting smoking, MMEF will return to normal. 
(Emmons et al 1992; Sherman 1992; Buist et al 1993).
These arguments could be convincing in advising female 
narguileh or cigarette smokers to quit, taking into consideration 
that, until now, the factors responsible for some smokers devel-
oping COPD while others do not is still unknown (Sherman 
1992; GOLD 2005). We can inform the patient or the smoker 
that when they present with CBH or an altered MMEF, they 
should stop smoking as these are risk factors for COPD.
Our results show also that narguilleh smoking causes 
pulmonary obstruction, but the presence of obstruction, 
expressed FEV1/FVC   70% of predicted, and its severity, 
expressed by the percentage of alteration of FEV1, is higher 
in cigarette smokers. This is true for either the cumulative 
quantity smoked, or the duration (p   0.001).
A former study in Saudi Arabia in both sexes showed that 
in both narguileh and cigarette smokers, the mean value of 
FEV1 and FVC was signiﬁ  cantly decreased when compared 
with controls, regardless of sex, and contrary to our results, 
the risk was in both sexes higher for narguileh (Al-Fayez et al 
1980). That could be explained by the fact that the more precise 
quantiﬁ  cation of the cumulative quantity smoked in our study 
was due to more subgroups. The Saudi study divided narguileh 
smokers into mild if they smoked only 2 sessions/day, and 
heavy if they smoked more. They also failed to consider 
Table 1 Population characteristics of the three groups
 NgS  (n  = 77)  CS (n = 77)  NS (n =100)
Mean age ± SD  40.99 ± 12.54  44.84 ± 10.55  39.13 ± 12.898
Domestic  Town 75 (97.5%)  Town 63 (81%)  Town 87( 87%)
Profession  Employed 6 (7%)  Employed 50 (64%)  Employed 58 (58%)
Chronic bronchitis  51 (67%)  40 (52%)  5 (5%)
Dyspnea  21 (27%)  40 (52%)  5 ( 5%)
MMEF   80%  75 (97%)  68 (88%)  7 (7%)
FEV1   80%  25 (32%)  51 (66%)  6 (6%)
Abbreviations: CS, cigarette smokers; FEV1, forced expiratory volume in one second; MMEF, ; NgS, narguileh smokers; NS, nonsmokers, control; SD, standard deviation.International Journal of COPD 2008:3(3) 410
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those who smoke narguileh only a few times per week. For 
cigarettes, they considered two categories of smokers: heavy 
if more than 20 cigarettes/day, and light smokers if less.
We will also remark that they used jurak and we used pure 
domestic tombac; the inﬂ  uence of these two brands in the 
pathogenesis of airﬂ  ow limitation has not been investigated 
yet. However, our two studies conﬁ  rm the role of narguileh 
smoke in airways obstruction.
Other former regional studies about narguileh showed:
•  Narguileh or goza smoking decreases the oxygen 
saturation in arterial blood more than cigarette smoking, 
which was considered to be due to the presence of a higher 
Chart 1 Alteration of MMEF* relative to the duration of smoking by female narguileh smokers versus cigarette smokers.
Note: The percentage of abnormal MMEF among narguileh smokers is independent of time, and at all times greater than the percentage among cigarette smokers. Value: 
p   0.001. The percentage of abnormal MMEF was 7% for the control nonsmoking group.
Abbreviation: MMEF, maximum mid-expiratory ﬂ  ow.
Chart 2 Alteration of MMEF relative to the quantity of tobacco smoked by female narguileh smokers versus cigarette smokers.
Notes: For narguileh smokers the percentage of abnormal MMEF is practically constant and independent of quantity.   Again the percentage for narguileh smokers is “always” 
higher than for cigarette smokers (p value  0.001).
Abbreviation: MMEF, maximum mid-expiratory ﬂ  ow.
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Chart 3 Chronic bronchitis relative to the duration of smoking by female narguileh smokers versus cigarette smokers.
Notes: The percentage of chronic bronchitis among narguileh smokers is greater at all times than that among cigarette smokers (p value  0.001) with Student t-test. The 
percentage of chronic bronchitis was 5% in the control nonsmokinggroup.
Chart 4 Chronic bronchitis relative to the quantity smoked by female narguileh smokers versus cigarette smokers.
Notes: For all quantity values, the percentage in narguileh smokers is higher than the one in cigarette smokers (p value = 0.001).
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quantity of carbon monoxide in narguileh smoke (Zahran 
et al 1985).
•  Narguileh smoking plays a role in transmitting respiratory 
infections, especially tuberculosis, by passing the tube 
from person to person, although it has a less carcinogenic 
effect (Omar and Salem 1996; Srinath 1996).
•  Low birth-weight was also documented in children of 
narguileh smoking women (Nuwayhid et al 1998).
Our study was limited by the following factors:
•  However we perform the quantiﬁ  cation of cumulative 
quantity smoked for naguileh, our process will remain 
open to criticism because it is very hard to record the 
Chart 5 FEV1 alteration relative to smoking duration in female narguileh smokers versus cigarette smokers.
Notes: In this graph the proportion of altered FEV1, for cigarette smokers is always higher than for narguileh smokers (p value  0.001). For the control group the percentage 
of abnormal FEV1 was 6%.
Abbreviation: FEV1, forced expiratory volume in one second.
Chart 6 Alteration of FEV1 relative to the quantity smoked in women narguileh smokers versus cigarette smokers.
Notes: The graph for cigarette smokers shows the same behavior as in the last duration diagram, the percentage of abnormal FEV1 augment with the cumulative quantity 
smoked. The percentage in narguileh smokers is approximately stable for all quantities. The two percentages start almost equal but the percentage then becomes greater in 
cigarette smokers than it is in narguileh smokers for all quantities (p   0.001).
Abbreviation: FEV1, forced expiratory volume in one second.
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effects of passing the narguileh buccal tube from one 
person to the other during the session, and measure the 
time that women take to chat while smoking narguileh. 
To overcome this, we divided the quantity smoked during 
one session by the number of women sharing it.
•  Another bias that we did not consider is passive smoking 
(Xu and Li 1995).
•  As with the Saudi study (Al-Fayez et al 1980), the func-
tional standard values used are for Caucasians. We lack 
standard values for our population.
Nonetheless, we feel that these factors are unimportant 
because the aim of our study was to highlight the underesti-
mated danger of the traditional pattern of smoking narguileh 
among women.
Pathological changes characteristic of COPD are found 
in the central airways, peripheral or small airways  2 mm 
of internal diameter, lung parenchyma, and pulmonary 
vasculature. Reversible components, which appear early, 
include edema, accumulation of inﬂ  ammatory cells, mucus 
hyper secretion, and smooth muscle contraction. Further 
exposure to tobacco smoke can induce, irreversible tissue 
damage, tissue remodeling, and ﬁ  xed airway obstruction 
expressed by the decrease in FEV1/FVC ratio and FEV1 
alteration in some individuals. Components of this irreversible 
ﬁ  xed obstruction are also the loss of parenchmal attachment 
and of elastic recoil, but small airways ﬁ  brosis and narrowing 
play the major role (GOLD 2005).
Could the reversibility of MMEF alteration after quit-
ting smoking reﬂ  ect the above mentioned transient revers-
ible pathological changes? And why does narguileh smoke 
provoke higher proportions of CBH and MMEF reduction? 
What are the pathogenetical mechanisms responsible for 
some patients at risk for COPD because their CBH and MEEF 
alteration may develop COPD and not others? Clearly, further 
research is needed.
Women share narguileh sessions in closed places, at their 
homes, and chronic respiratory symptoms provoked by this 
environmental tobacco-smoke in children is another potential 
area for research (US Surgeon General 2006).
Conclusion
Our results illustrate the need to change the public opinion 
on narguileh, and to encourage antitobacco campaigns. Both 
narguileh and cigarette smoking is harmful, but special 
attention toward narguileh smoking is recommended in 
our region because women traditionally smoke together in 
closed places with children around. This is a problem of 
indoor environmental tobacco smoke. This study has been 
considered by the health ministry in Syria to involve the harm 
of narguileh smoke in the National Program of Anti-Tobacco 
Campaign in Syria.
When performing spirometry with a smoker, it provides 
one with the opportunity to convince them to quit (Gary 
et al 2000). The following arguments could be convincing: 
quitting may provide a chance for the altered MMEF to 
return to normal (Teculescu et al 1989; Emmons et al 
1992; Buist et al 1994) and prevent a potential obstruction 
if FEV1 is still normal, or to reduce the annual decline of 
FEV1 if this value had been already altered (Camilli et al 
1987; Hugues et al 1987; Emmons et al 1992; US Surgeon 
General 1994). These are part of the recommendations of 
the National Lung Health Education Program in the USA, 
and are true for both cigarettes and narguileh, especially 
when we know that obstruction can precede symptoms by 
several years in some cases.
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